Prognostic parameters in patients with resected liver metastases from colorectal cancer after biological and chemotherapy

Miljana Džunić; Ivan Petković; Ana Cvetanović; Ivica Pejčić; Svetislav Vrbić; Saša Dinić

doi:10.5937/afmnai2004349d

Original article

Published: 01.12.2019.

<< Prev | Next >>

PDF

https://doi.org/10.5937/afmnai2004349d

Prognostic parameters in patients with resected liver metastases from colorectal cancer after biological and chemotherapy

Abstract

The aim of the research was to investigate prognostic factors in patients with resected colorectal liver metastases (CLMs) after biological and chemotherapy, which made initially unresectable disease suitable for resection. Sixty-six patients with resected CLMs, operated after induction bio-chemotherapy with bevacizumab + FOLFOX4, treated at the Clinic of Oncology, Clinical Center Niš from 2010 - 2017 were included. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test according to demographic characteristics, characteristics of the disease and the treatment. A univariate COX regression analysis was performed. In patients with up to 4 CLMs, DFS was significantly longer than in patients with five or more metastases (18,384 v.s. 6,85 months; p < 0,001). Significantly longer OS was present in patients with up to four CLMs than in those with five or more CLMs (44,687 v.s. 29,723 months; p = 0,006) and in patients without extrahepatic disease (41,71 v.s. 23,283 months; p = 0,012). In the univariate analysis, five or more CLMs were predictors of poorer DFS (HR 3,989; 95% CI 1,055 - 15,087; p = 0,042), whereas the absence of extrahepatic disease was a predictor of better OS (HR 0,122; 95% CI 0,017 - 0,869; p = 0,036). Results of this research are in concordance with previous larger studies in patients with resected CLMs. The number of hepatic and the presence of extrahepatic metastases are prognostic parameters in patients with resected CLM after conversion bio-chemotherapy.

Keywords:

colorectal cancer,

liver,

metastases,

prognosis,

surgery

References

Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, et al. Extension of the Frontiers of Surgical Indications in the Treatment of Liver Metastases From Colorectal Cancer. Annals of Surgery. 2000;231(4):487–99.

Dzunic M, Petkovic I, Cvetanovic A. Current and future targets and therapies in metastatic colorectal cancer. J BUON. 2019;24(5):1785–92.

Wang Z, Wang X, Zhang Z, Wang X, Chen M, Lu L, et al. Association between Primary Tumor Location and Prognostic Survival in Synchronous Colorectal Liver Metastases after Surgical Treatment: A Retrospective Analysis of SEER Data. Journal of Cancer. 2019;10(7):1593–600.

Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F. One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants. Journal of British Surgery. 1991;78(7):797–801.

Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut C. A study of prognostic factors for hepatic resection for colorectal metastases. The American Journal of Surgery. 1997;173(6):467–71.